PRAD ranks as the primary cause of mortality among men [72], and inherently exhibits resistance to ICBs [73], and neither monotherapy targeting anti-PD-1/PD-L1 nor anti-CTLA-4 demonstrates a significant impact on the overall survival of prostate cancer patients [74, 75]. Here, CD274 is linked to prostate adenocarcinoma.